共 192 条
[1]
Ajeganova S(2013)Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study J Rheumatol 40 1958-1966
[2]
Andersson ML(2002)Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis Obs Study J Rheumatol 29 1631-1638
[3]
Frostegard J(2003)Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis Ann Rheum Dis 62 482-486
[4]
Hafstrom I(2007)Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility Ann Rheum Dis 66 iii56-60
[5]
Aletaha D(2016)Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration Adv Ther 33 369-378
[6]
Smolen JS(2011)Understanding emerging treatment paradigms in rheumatoid arthritis Arthritis Res Ther 13 S3-332
[7]
Aletaha D(2013)Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis Arthritis Res Ther 15 R217-1598
[8]
Kapral T(2014)Folic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritis Clin Exp Rheumatol 32 324-1398
[9]
Smolen JS(2016)Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systematic review Ann Rheum Dis 75 1595-515
[10]
Bakker MF(2005)The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom general practice research database Rheumatology (Oxford) 44 1394-269